Q1 FY26 Quarterly Investor Presentation & Webinar
Released
Released
Announcement PDF
ASX Announcement
28 October 2025
JOIN MICROBA’S INTERACTIVE INVESTOR HUB
For more Company information and to engage with management by asking questions about Microba’s latest
announcements and updates, visit ir.microba.com/welcome
Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621
Q1 FY26 Quarterly Investor Presentation & Webinar
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to provide below its Q1 FY26 Investor
Presentation and Investor Webinar with CEO, Dr Luke Reid presenting.
Quarterly Investor Webinar
Presented by: CEO, Dr Luke Reid
Date & Time: 11:00am AEST (Brisbane) / 12:00pm (midday) AEDT (Sydney/Melbourne) on Tuesday, 28 October 2025
Webinar Registration: Registration is required to attend the Quarterly Investor Webinar. Please register for the Webinar via
Microba’s Investor Hub at the following link: https://ir.microba.com/webinars/0y52Ge-q1-fy26-quarterly-investor-webinar
Webinar Recording: A recording will be made available at the same link following the conclusion of the live webinar.
Submit Your Questions
We invite investors and interested parties to submit questions ahead of the Quarterly Investor Webinar through the ‘Ask a
question’ section of Microba’s interactive investor platform by following this link: https://ir.microba.com/webinars/0y52Ge-
q1-fy26-quarterly-investor-webinar
Stay Informed
To receive notifications when Microba releases its Quarterly Reports & Appendix 4C, Investor Presentations, and other key
announcements, sign up to the Microba Investor Hub:
1. Visit https://ir.microba.com/welcome
2. Follow the prompts to sign up for an account.
3. Complete your account profile.
This announcement has been authorised for release by the Board of Directors
For further information, please contact:
Dr Luke Reid
Chief Executive Officer
luke.reid@microba.com
https://ir.microba.com/welcome
About Microba Life Sciences Limited
Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology
for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for
major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers.
Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the
microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com
At the forefront of microbiome
diagnostics & therapeutics
Q1 FY26 Results
Authorised for release by the Board of Directors
ASX: MAP
28 OCTOBER 2025
2
Disclaimer
This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba).
Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its absolute discretion, but without being under any
obligation to do so, update or supplement this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in
evaluating a possible investment in Microba or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act).
Industry and market data – In this Presentation, Microba refers to certain market, industry, and statistical data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including
industry or general publications. Neither Microba nor its representatives have independently verified any such data and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy.
Some data is also based on the good faith estimates of Microba, which are derived its reviews of internal sources as well as the independent sources described above.
Not an offer - This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is
not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this Presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this Presentation, you
should observe such restrictions and should seek your own advice. Any non-compliance with these restrictions may contravene applicable securities laws.
Not investment or medical advice - The information contained in this Presentation is not investment, financial product advice, medical advice or any medical recommendation or recommendation to acquire Shares. This Presentation has been
prepared without taking into account your investment objectives, financial situation, medical or any other particular needs This Presentation does not and will not form any part of any contract for the acquisition of shares. Each recipient of this
Presentation should make its own enquiries and investigations regarding all information in this Presentation. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment
objectives, financial situation and particular needs and having regard to the merits or risks involved. Independent financial advice is recommended.
Future performance - This Presentation contains forward looking statements. Forward-looking statements generally relate to current expectations, hopes, beliefs, intentions, strategies or productions about future events or Microba's future financial
or operating performance. For example, statements regarding anticipated growth in the industry in which Microba operates and anticipated growth in demand for Microba's products and services, projections of Microba's future financial results and
other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect",
"intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-
looking. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward looking
statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of
Microba. You are cautioned not to place undue reliance on any forward looking statement. Forward looking statements in this Presentation are based on assumptions and contingencies which are subject to change without notice. Actual results,
performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. The forward looking statements in this Presentation are based on information available to Microba as at
the date of this Presentation and nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking
statements will be achieved. Except as required by law or regulation, Microba undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.
Financial data – All dollar values in Australian dollars (A$ or $) unless otherwise stated. Recipients should note that this Presentation contains historical and pro-forma financial information. Any financial information provided in this Presentation is for
illustrative purposes only and is not represented as being indicative of Microba’s views on its future financial condition and/or performance.
Trademarks – This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in
this Presentation may be listed without the © or ® symbols, but Microba asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright.
Disclaimer - Except for any statutory liability which cannot be excluded, Microba, its related bodies corporate and their respective officers, employees and advisers expressly disclaim all liability (including negligence) for any direct or indirect loss or
damage which may be suffered by any person in relation to, and take no responsibility for, any information in this Presentation or any error or omission therefrom, and make no representation or warranty, express or implied, as to the currency,
accuracy, reliability or completeness of this Presentation.
3
Key Risks & Forward Financial Information Assumptions
Forward Financial Information Assumptions
The achievement of the FY26 forward information & ~3-year strategic objectives detailed in slide 4 is
based on the below key assumptions, and deviation in the Company’s ability to achieve or not achieve
these key assumptions, may materially affect the Company’s ability to execute these objectives. Refer
to slide 2 for the general disclaimer relating to 'future performance'. The assumptions specific to the
FY26 forward information & ~3-year strategic objectives are set out below.
FY26 Outlook Assumptions
• YoY core test volume growth of 100% assumes continued clinician adoption growth in Australia and
the UK market.
- Increased clinician adoption, including continued growth of new clinician accounts and
maintenance of existing test referral rates in Australia & the United Kingdom
- New product feature releases.
FY26 break-even milestones - Assumptions
• Based on operating break-even at a regional level (forecasted to be achieved at test volumes of
>24,000, split across Australia and the UK)
• Break-even figures are on a regional EBITDA basis only and exclude Corporate, Product
Development Expenditure and Share Based Payments expense.
• Australia break-even and UK break-even figures are based on forecast test pricing, targeted gross
margins, and assumed operating cost structures for each geography.
• Test pricing and gross margins are assumed to remain stable over FY25–FY26, with no material
changes.
• Operational costs assume continued efficiencies from fixed infrastructure and modest scaling of
commercial and support functions, including advancement and implementation of product-
assisted/led growth models.
• UK break-even assumptions are modelled using an AUD:GBP exchange rate of 0.48.
• Assumes no material disruption from regulatory changes, macroeconomic & geopolitical shifts, or
competitive pricing actions.
• Forecasts are contingent on execution of FY26 revenue plan and sufficient capital allocation to
support commercial execution and product development.
~3 Year Strategic Objective Assumptions
Group EBITDA Break-even - Assumptions
• Group break-even assumes successful execution of the FY26 regional break-even milestones (see
above), followed by further scale in existing markets.
• Assumes that Operating Expenses, Product Development and Corporate Expenditure grow at a rate
below revenue growth, enabling operating leverage.
• Assumes that new geographies or product development programs do not materially increase
operating expenditure during the period.
Strong YoY Core Test Growth – Australia & United Kingdom – Assumptions
• Growth targets assumed in the Group EBITDA Break-even plan assumes continued strong clinical
adoption by innovator and early adopter clinicians and broader market penetration.
• Assumed strong YoY growth is dependent on the availability of sufficient capital to support planned
commercial expansion, product development and operational scaling. In the event that capital is not
secured at anticipated levels, these objectives may be delayed or may not be achieved.
Initial Market Penetration – United States & Europe – Assumptions
• Assumed core test pricing aligned with existing competitor predicate tests in market.
• Entry into the US and Europe is expected to be limited to one initial geography in each region.
• Assumes Laboratory Developed Test (LDT) regulatory pathway remains accessible in the US, and
CLIA accreditation is achieved for Microba central laboratory in Australia to service the initial
development of the US market
• Assumes successful establishment of laboratory service partnership and logistics with The Doctors
Laboratory (a subsidiary of Sonic Healthcare) to service volume from the UK and Europe
• Assumes supportive regulatory, geopolitical and tariff environment and no material delays in market
access.
• Assumes no requirement for reimbursement, cash pay sales are considered only.
• Modest investment has been included, no material CAPEX expenditure has been incorporated, with
existing and partner laboratories utilised to service growth in test volume.
Transformative Patient Outcomes – Assumptions
• Qualitative and based on the frequency of patient outcomes shown from existing study data on
Microba’s core tests, and the anticipated growth in patient test usage and resulting continued
growth in clinician adoption
4
~3 Year
Strategic Objective
$15.67m
Revenue
161%
YoY core test growth
Expand clinical adoption.
Break-even in Australia &
United Kingdom1.
12,631
Core test volume
Regional Break-even
In Australia & United Kingdom1
Strong penetration of
innovator & early adopter
clinicians. Transformative
patient outcomes across
core regions.
Grow early clinical adoption.
UK market expansion.
United States
Momentum in first state
Europe
Momentum in first country
FY25
United Kingdom
Strong YoY growth
“We are building the platform
for personalised, microbiome-
based healthcare.”
Australia
Strong YoY growth
Break-even
Group EBITDA
The information on this slide includes forward financial information (Forward Financial Information). The Forward Financial Information has been prepared by Microba Life Sciences Ltd based on management best estimate assumptions which relate to future event(s) that Microba expects to occur and actions
that Microba expects to take and are also subject to uncertainties and contingencies, which are often outside the control of Microba. While all reasonable endeavours have been made to ensure both the robustness of the assumptions on which the Forward Financial Information is based and that such
assumptions are true, complete and accurate, such assumptions are generally future-oriented and therefore speculative in nature. 'Refer to slide 2 Financial Information Assumptions') for detail on both the assumptions and risks underpinning the FY26 numbers and ~3 Year Strategic Objective.
>100%
YoY core test growth
FY26
>24,000
Core test volume
5
SECTION 1
Q1 FY26 Results
Financial Highlights
6
Q1 Financial Highlights
Core test volume run-rate reaches 20,000 tests globally, on track for FY26 regional break-
even guidance
Q1 core tests 4,931, up 145% vs PCP
Australia
• Record Q1 MetaXplore tests sales of 3,884, up 112% vs PCP
• Q1 MetaXplore annualised run-rate of 15,500+ tests sold, up 112% vs PCP
• Steady Q1 MetaPanel test sales of 264 tests, up 44% vs PCP
• Q1 MetaPanel annualised run-rate of 1,000+ tests sold, up 44% vs PCP
United Kingdom
• Record Q1 MetaXplore test sales of 783, up 83% QoQ (no PCP)
• Q1 MetaXplore annualised run-rate of 3,100+ tests sold, (no PCP)
• MetaXplore tests now represent 100% of GI tests sold, all legacy UK testing
products discontinued as of 30 September
0
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
4,500
5,000
5,500
Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26
Continued Growth in Test Volumes
MetaXplore (AUS) MetaPanel (AUS) MetaXplore (UK)
+145%
7
• Growth product revenue of $1.9m, up 151% vs PCP
• Base product revenue of $1.3m, down 15% vs PCP
• Legacy product revenue of $0.4m, down 73% vs PCP
• Through disciplined cost management, operating expenditure has been cut by more than 26% in Q1 FY26
versus Q4 FY25 (excluding one-off and restructuring items)
• Replaced over $1m of discontinued Legacy product revenue in Q1 FY26. Legacy product revenues will
conclude by the end of Q2 FY26.
• Q1 Total Revenue of $3.6m, down 1% vs PCP aligned to strategic discontinuation of legacy product
revenue. Excluding Legacy products revenue grew 42% vs PCP.
Q1 Financial Highlights
Strong growth of core products, disciplined cost management.
Growth product revenue of $1.9m, up 151% vs PCP.
8
Growth
Core tests & clinical software
winning a major new $25B
diagnostic category
Legacy
Products & services being discontinued &
phased out.
(Research services, UK EcologiX test, AU Insight test)
Strong clinical adoption & accelerating growth
Base
To continue with opportunity
for future growth.
(Supplements, Strategic International Partners)
Chart X-axis are sales in AUD; revenue recognition timing differs.
$0
$500,000
$1,000,000
$1,500,000
$2,000,000
$2,500,000
Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26
$0
$1,000,000
$2,000,000
Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26
$0
$1,000,000
$2,000,000
Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26
9
SECTION 2
Q1 FY26 Results
Business Highlights
10
SUB-SECTION 2.1
KEY HIGHLIGHTS
11
Practitioner Pays
A new payment workflow allowing healthcare
practitioners to order and pay for MetaXplore
tests directly on behalf of their patients.
This feature streamlines the ordering process
by enabling the clinician to bundle and
manage payment directly with the patient,
removing patient payment steps, and
increasing conversion. Practitioners can fully
integrate MetaXplore testing into their clinical
services and enable payment at their clinic as
a part of their service package, improving
workflow efficiency, customer experience,
and reducing referral friction.
This feature directly supports the needs of key
target healthcare professionals and clinics.
New Product Feature Releases
Released into MetaXplore August 2025
12
Admin Accounts
Admin Accounts is a new feature within the
Practitioner App designed to ease the
administrative workload in busy, multi-
practitioner clinics.
Admin Accounts allow designated support staff
to manage patient records, referrals, and reports
on behalf of practitioners, while maintaining full
transparency and compliance. Practitioners
retain complete oversight, receiving notifications
and audit logs of all actions. By reducing manual
data entry and delegation bottlenecks, Admin
Accounts enable practitioners to focus more
time on patient care.
This feature directly supports the needs of key
target healthcare professionals and clinics.
New Product Feature Releases
Released into MetaXplore October 2025
13
Microba will release a major brand update in November. This will consolidate our global brands, drive
further operational efficiencies, and increased marketing effectiveness to increase sales and lower
costs.
Q2 Brand Consolidation & Update
14
SUB-SECTION 2.2
GROWTH
Core tests & clinical software winning a major new
$25B diagnostic category
15
Growing MetaXplore sales
and clinical adoption in Australia
Q1 – Continued strong sales growth
• 3,884 tests sold, up 112% vs PCP
• Annualised run-rate of >15,500 tests, up
112% vs PCP
• 837 ordering clinicians, up 71% vs PCP
• Supported by consistent clinician
engagement, focused field activity,
ongoing product enhancements, and
continued growth in ordering clinicians,
and increased tests per ordering clinician
Q1
387
526
738
1035
837
H1 FY24 H2 FY24 H1 FY25 H2FY25 Q1FY26
MetaXplore Ordering Clinicians (AU)
1782
2907
4392
6673
3,884
H1FY24 H2FY24 H1FY25 H2FY25 Q1FY26
MetaXplore Test Sales Volume (AU)
Q1 FY26
Q1 FY26
16
Growing MetaXplore sales and clinical
adoption in the United Kingdom
Q1
Q1 – Continued strong sales growth
• 783 tests sold, up 83% QoQ (no PCP
comparison)
• Annualised run-rate of 3,100 tests sold, (no
PCP comparison)
• 299 ordering clinicians, up 84% QoQ (no
PCP comparison)
• Through strategic clinician education,
targeted field sales execution, product
enhancements and market development
through key industry events.
22
675
783
0
200
400
600
800
1000
1200
1400
H1FY25 H2FY25 Q1FY26
MetaXplore Test Sales Volume (UK)
26
175
299
0
50
100
150
200
250
300
350
H1FY25 H2FY25 Q1FY26
MetaXplore Ordering Clinicians (UK)
Q1 FY26
Q1 FY26
17
Growing MetaPanel sales and clinical
adoption in Australia
Q1 - Steady sales
• 264 tests sold, up 44% vs PCP
• Focus remains on organic development of
Gastroenterology specialists which will drive
adoption activity in the rest of the clinician
market.
• We expect a gradual rate of adoption over the
next year, with subsequent years providing the
opportunity for larger volume as our consistent
Key Opinion Leader (KOL) and evidence
development work starts to yield results in
routine usage.
155
402
465
264
H2FY24 H1FY25 H2FY25 Q1FY26
MetaPanel Test Sales Volume (AU)
104
255
306
168
H2FY24 H1FY25 H2FY25 Q1FY26
MetaPanel Ordering Clinicians (AU)
Q1 FY26 Q1 FY26
18
SUB-SECTION 2.3
BASE
Supplements and International Partners.
19
Supplement sales & revenue in
United Kingdom
Growth focused on Invivo owned products
• Invivo branded and owned supplements sales
$0.66m, up 7% vs PCP
• Leading PHGG prebiotic supplement up 84% vs
PCP
• Total supplement sales $1.0m, down 20% vs
PCP reflecting further acceleration of the
transition to a greater focus on our higher
margin Invivo branded and owned
supplements vs third party distributed Designs
For Health (DFH) branded products
Q1
United Kingdom
0
10,000
20,000
30,000
40,000
50,000
60,000
70,000
80,000
H1FY25 H2FY25 Q1FY26
Supplement Unit Sales (UK)
Invivo DFH
$0
$500,000
$1,000,000
$1,500,000
$2,000,000
$2,500,000
$3,000,000
H1FY25 H2FY25 Q1FY26
Supplement Revenue (UK)
Invivo DFH
Q1 FY26 Q1 FY26
20
SUB-SECTION 2.4
THERAPEUTICS
Attractive upside - leveraging Microba’s leading
databank with years of R&D and investment
21
Attractive Upside
A pipeline of assets backed by big-data, preclinical and
clinical validation, targeting deals
LBP = Live Biotherapeutic Product
• 5+ years of investment to develop a rich
pipeline of live biotherapeutic assets
and data, leveraging Microba’s world
leading databank generated from it’s
testing business
• Now moved to partnering to provide a
return on investment for shareholders
• Microbiome therapeutics sector will see
upcoming sector deal catalysts, first
before end of CY2025
• No further R&D expenditure from FY26
• Recent deal precedents ranging
between $1.5 – $11B
Therapeutic Assets
Upcoming deal catalysts
Deal Catalysts
Two more peer companies are expected to read out on key clinical trials by the end of 2025. The results from these trials
if positive would validate this new live-biotherapeutic modality, and deal precedents indicate that competitive deal
activity for these assets would follow. Microba’s leading data-driven platform and live-biotherapeutic assets, are best in
class and ready for this deal activity.
Microbiotica - Phase 1b First-in-Human trial, COMPOSER-1, for MB310 in ulcerative colitis (UC)
patients. Expected to read out before the end of CY25
Vedanta – Global, randomized, double-blind, placebo-controlled Phase 2 study COLLECTiVE202, for
VE202 in patients with mild-to-moderate UC. 13 Aug 2025 - did not meet their end points.
Siolta - Phase 1b/2, randomized, double-blind, multi-center study to evaluate the preliminary clinical
efficacy of STMC-103H in neonates and infants at risk for developing allergic disease. Expected to
read out before the end of CY25
22
SUB-SECTION 2.5
FOCUS & CATALYSTS
23
Key areas of focus & catalysts
Diagnostics
• Australia - continued growth in test sales and clinical
adoption
• United Kingdom - continued growth in test sales
and clinical adoption
• Multiple upcoming MetaXplore feature releases
• Brand update and consolidation launch
Therapeutics
• 2 upcoming sector deal catalysts, expected in late
CY2025.
FY26 Guidance
• Regional Break-even in Australia & United Kingdom
• >24,000 Core test volume (Q1 annualised run rate of
~20,000)
Financial Snapshot
ASX Code MAP
Market capitalisation1 $51m
Shares on issue 608.96m
52-week low / high1 $0.076 / $0.325
Cash Balance (30 Sept 2025) $13.89m
Major Shareholders
Shareholder Ownership %2
Sonic Healthcare 19.14%
Perennial 13.47%
Thorney Investment Group 6.86%
SA Microba Holdings 6.50%
1 At 27 October 2025 | 2 At 30 June 2025
24
SECTION 3
Microba Overview
Whole Business Recap
25
SUB-SECTION 3.1
The Microbiome Opportunity
The next frontier in precision healthcare
26
PubMed search terms "gut microbiome" and "modulate" and "clinical study" and manually selecting for clinical trials with positive results indicated in the abstracts.
150+
Global clinical studies
demonstrate that microbiome
modulation can influence disease
outcomes and clinical symptoms*
Changing the gut microbiome can treat chronic disease.
Cancer
Mental Cardiovascular Autoimmune Allergy
Gastrointestinal
21,000+
Research publications
demonstrate a clear link
between chronic diseases and
the gut microbiome*
27
Clear, global and ambitious vision
Millions of patients
living healthier lives
Microbiome diagnostics
and therapeutics have
materially improved
millions of patient lives –
driving yet further
awareness and adoption.
Usage of approved
therapeutics is
routine
Microbiome therapeutics
are approved and in
routine use for both
maintenance and
the treatment of multiple
chronic diseases.
Regular testing is
commonplace
High quality and
clinically useful
microbiome testing is
performed regularly –
initiated both by
patients and clinicians.
Broad-based
acceptance
The microbiome is
recognised by
healthcare professionals
and patients as critical
to health and disease
management.
28
Combating chronic disease through
microbiome diagnostics and therapeutics
Microbiome testing to diagnose and match
patients with the right treatment
Microbiome therapy to treat
chronic diseases
$125B Est. TAM $1.3T Est. TAM
$1.4 trillion healthcare disruption opportunity
Management estimate based on desktop study of the total number of patients across the top 10 chronic diseases impacted by the microbiome, across the United States, United Kingdom, Australia, France, Germany, Spain & Italy. Conservative diagnostic and therapeutic
pricing in USD applied based on existing predicates.
29
Unlocking the $1.4 trillion healthcare disruption
opportunity
3 programs.
Two tests.
Clinical microbiome testing
Diagnostics
World leading microbiome analysis technology | Proprietary databank | Advanced AI and biostatistics
GASTROINTESTINAL
PATHOGEN TEST
GASTROINTESTINAL
DISORDERS TEST
Precision microbiome therapeutics
Therapeutics
INFLAMMATORY BOWEL DISEASE PROGRAM
CLINICAL INDICATION
Mild-moderate Ulcerative Colitis
IMMUNO-ONCOLOGY PROGRAM
CLINICAL INDICATION
Multiple cancers to enhance check-point
inhibitor response
AUTOIMMUNE DISEASE PROGRAM
CLINICAL INDICATION
Lupus, psoriatic arthritis & liver disease
• Opening a $100B new
diagnostic category.
• Focus today $25B market -
patients with unresolved GI
disease
• Accelerating traction in first two
markets – Australia & United
Kingdom
• FY25 revenue $15.67m
• Regional break-even
milestones targeted in FY26
World leading partners
• 5 years of R&D established
pipeline of live biotherapeutic
assets
• Deep preclinical and early
clinical validation
• Transitioned from R&D to
partnering focus
• $1.5b to $11B deal precedents
• Upcoming sector deal
catalysts before end of
CY2025
2 commercial value streams
PHARMA PROBIOTIC
30
SUB-SECTION 3.2
DIAGNOSTICS
Products, TAM & Clinical Data
31
Gastrointestinal pathogen test
Launched March 2024
Stool DNA test.
175 targets.
Expertly curated clinical recommendations for targeted treatment.
Gastrointestinal disorder test
Launched February 2023
Stool DNA + targeted biomarker test.
7 functional GI markers. >28k microbiome markers.
Expertly curated clinical recommendations for personalised treatment.
Second line
Identifying functional
causes and treatment
options for
non-pathogenic
GI symptoms
First line
Diagnosing
pathogenic causes
of GI symptoms
Addressing the GI symptom challenge
Microba’s comprehensive diagnostic products
32
1 Assessment of Medicare claims analysis. Estimated Private and Medicaid numbers extrapolated from Medicare claims analysis completed with Boston based MedTech specialist consultancy Veranex Inc., 2 Gordon, J., Miller, G., &
Valenti, L. (2015). The management of unresolved gastrointestinal symptoms in Australian general practice. Australian Family Physician, 44(9), 621-623, 3 Aggregate results from released clinical studies of MetaXplore (4,616)
and MetaPanel (889) patient results, 4 Aggregate results from patient survey results of MetaXplore (n=84), and clinical study results from MetaPanel (n=6) patient results
GI disease is a silent epidemic
New answers and resolution for millions of patients suffering
82,690,000
patients suffering
Presenting annually with lower GI abdominal
symptoms across 7 top countries 1
49.6m
Pain, bloating, constipation, other
1.4m
IBD & Other % of patients achieving resolution of
gastrointestinal symptoms after 5
years2
47%
Unresolved
>70%
get new results
Demonstrated in studies on over 5k patients
across MetaXplore and MetaPanel 3
50%
no resolution with
routine care
Share your feedback
Discover